The administrative core is responsible for the operation of the program and supervision of the conduct of the proposed grant. The core facilitates communication between investigators and visits of outside investigators to MD Anderson Cancer Center. The core maintains the central databases for the clinical and translational research described in the projects as well as the GMP - Immune Assessment Core (Core E). The core supports the FDA IND submissions and reporting required for protocols in the POI. The core manages program personnel and budgets for each section ofthe grant. The core is responsible for preparing reports for the research projects and publications. The CML group meets multiple times per week in meeting related to leukemias, stem cell transplantation and specific laboratory research related to this program. We discuss the design, status and results of clinical and laboratory research, sample acquisition, status of patients participating on clinical research studies, pathology, cytogenetic, molecular analysis review. This includes a weekly CML POI program meetings and broader meetings involving the Leukemia, Stem Cell Transplant and Cellular Therapy (SCTCT) and Molecular Pathology programs. Specifically, the Administrative Core has the following objectives to accomplish: ? Provide leadership to and oversight of the cores and research projects ofthe Program. ? Convene all necessary meetings, including meetings ofthe External Scientific Advisory Board, regularly scheduled meetings of the investigators, and discussion of all the clinical trials in the program. ? Prepare grant continuation submissions for the NCI and to comply with internal reporting requirements. ? Coordinate data quality control and quality assurance in conjunction with the Biostatistics and other projects and cores. ? Monitor and control expenditures and maintain budget information. ? Track and maintain record of all publications, including abstracts and manuscripts, resulting from the program project.

Public Health Relevance

The administrative core oversees this CML program project grant under the leadership of Dr. Champlin. Core A monitors the progress from each project and core and ensure the proper use of funding. Core A also supervises the conduct of clinical research and ascertain the regulatory compliance and HIPAA regulations are followed.

National Institute of Health (NIH)
National Cancer Institute (NCI)
Research Program Projects (P01)
Project #
Application #
Study Section
Special Emphasis Panel (ZCA1-RPRB-J)
Project Start
Project End
Budget Start
Budget End
Support Year
Fiscal Year
Total Cost
Indirect Cost
University of Texas MD Anderson Cancer Center
United States
Zip Code
Qazilbash, M H; Wieder, E; Thall, P F et al. (2016) PR1 peptide vaccine induces specific immunity with clinical responses in myeloid malignancies. Leukemia :
Jain, Preetesh; Kantarjian, Hagop; Sasaki, Koji et al. (2016) Analysis of 2013 European LeukaemiaNet (ELN) responses in chronic phase CML across four frontline TKI modalities and impact on clinical outcomes. Br J Haematol 173:114-26
Tripathi, Satyendra C; Peters, Haley L; Taguchi, Ayumu et al. (2016) Immunoproteasome deficiency is a feature of non-small cell lung cancer with a mesenchymal phenotype and is associated with a poor outcome. Proc Natl Acad Sci U S A 113:E1555-64
Andreeff, Michael; Kelly, Kevin R; Yee, Karen et al. (2016) Results of the Phase I Trial of RG7112, a Small-Molecule MDM2 Antagonist in Leukemia. Clin Cancer Res 22:868-76
Jain, Preetesh; Kantarjian, Hagop; Patel, Keyur P et al. (2016) Impact of BCR-ABL transcript type on outcome in patients with chronic-phase CML treated with tyrosine kinase inhibitors. Blood 127:1269-75
Chen, Z; Cortes, J E; Jorgensen, J L et al. (2016) Differential impact of additional chromosomal abnormalities in myeloid vs lymphoid blast phase of chronic myelogenous leukemia in the era of tyrosine kinase inhibitor therapy. Leukemia 30:1606-9
Hoehn, Daniela; Cortes, Jorge E; Medeiros, L Jeffrey et al. (2016) Multiparameter Analysis of Off-Target Effects of Dasatinib on Bone Homeostasis in Patients With Newly Diagnosed Chronic Myelogenous Leukemia. Clin Lymphoma Myeloma Leuk 16 Suppl:S86-92
Lee, Dean A; Denman, Cecele J; Rondon, Gabriela et al. (2016) Haploidentical Natural Killer Cells Infused before Allogeneic Stem Cell Transplantation for Myeloid Malignancies: A Phase I Trial. Biol Blood Marrow Transplant 22:1290-8
Cortes, Jorge E; Lipton, Jeffrey H; Miller, Carole B et al. (2016) Evaluating the Impact of a Switch to Nilotinib on Imatinib-Related Chronic Low-Grade Adverse Events in Patients With CML-CP: The ENRICH Study. Clin Lymphoma Myeloma Leuk 16:286-96
Khorashad, J S; Tantravahi, S K; Yan, D et al. (2016) Rapid conversion of chronic myeloid leukemia to chronic myelomonocytic leukemia in a patient on imatinib therapy. Leukemia 30:2275-2279

Showing the most recent 10 out of 325 publications